Journal article

Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany (vol 17, 276, 2022)


Authors list: Hahn, Andreas; Guenther, Rene; Ludolph, Albert; Schwartz, Oliver; Trollmann, Regina; Weydt, Patrick; Weiler, Markus; Neuland, Kathrin; Schwaderer, Martin Sebastian; Hagenacker, Tim

Publication year: 2022

Journal: Orphanet Journal of Rare Diseases

Volume number: 17

Issue number: 1

eISSN: 1750-1172

Open access status: Gold

DOI Link: https://doi.org/10.1186/s13023-022-02548-7

Publisher: BioMed Central



Citation Styles

Harvard Citation style: Hahn, A., Guenther, R., Ludolph, A., Schwartz, O., Trollmann, R., Weydt, P., et al. (2022) Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany (vol 17, 276, 2022), Orphanet Journal of Rare Diseases, 17(1), Article 387. https://doi.org/10.1186/s13023-022-02548-7

APA Citation style: Hahn, A., Guenther, R., Ludolph, A., Schwartz, O., Trollmann, R., Weydt, P., Weiler, M., Neuland, K., Schwaderer, M., & Hagenacker, T. (2022). Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany (vol 17, 276, 2022). Orphanet Journal of Rare Diseases. 17(1), Article 387. https://doi.org/10.1186/s13023-022-02548-7


Last updated on 2025-10-06 at 11:45